MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.

MPM Capital

EcoR1 Capital is an investment advisory firm focused on the biotech industry. They aim to identify and evaluate innovative therapeutic solutions that can bring significant improvements to patients' lives. Drawing inspiration from the transformative power of the EcoR1 restriction enzyme in the biomedical field, they invest in biotech companies that offer promising new treatments for untreated diseases. EcoR1 Capital recognizes the importance of building upon the innovative contributions of its predecessors in order to continue advancing medical research.

EcoR1 Capital

Vida Ventures’ mission is to bring science to life by advancing transformative biomedical innovations that have the potential to make a meaningful impact on the lives of patients. They want to do well by doing good for others. Vida Ventures is a bicoastal life sciences company building and investment firm, founded in 2017 by a group of scientists, physicians, entrepreneurs, and investors who are passionate about building and funding breakthroughs in biomedicine  .

Vida Ventures

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products.  Bristol Myers Squibb focuses on areas such as oncology, cardiovascular, immunoscience, and fibrosis to develop therapies that address significant unmet medical needs. The company's research and development efforts are centered around discovering new drugs and advancing existing ones to improve patient outcomes. BMS has a diverse portfolio of medicines, including several blockbuster drugs used in the treatment of cancer and other diseases. The company is committed to advancing the science of medicine to help people fight serious diseases and improve their quality of life.

Bristol-Myers Squibb

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.  Their mission is to discover new ways to improve and extend people's lives.  They apply their expertise in science and innovation to society’s biggest health challenges. Responsibility is a core part of their business strategy.

Novartis

Octagon Capital invests in public and private healthcare companies globally. Octagon Capital focuses on strategic long-term investments and strive to work with our portfolio management teams as partners.

Octagon Capital Advisors

TCG X is a healthcare investment firm dedicated to advancing disruptive medicines and supporting companies that can improve the lives of patients. TCG X invests in both private and public companies led by exceptional entrepreneurs focused on developing better treatment options for patients. TCG X has investment teams in Palo Alto and New York City

TCG Crossover

Merck (d.b.a. EMD Millipore in the U.S. and Canada) is a German chemical and pharmaceutical company. Merck, also known as “German Merck” and “Merck Darmstadt”, was founded in Darmstadt, Germany, in 1668, making it the world's oldest operating chemical and pharmaceutical company. The company was privately owned until going public in 1995. However, the Merck family still controls a majority (≈70%) of the company's shares. Following World War I, Merck lost possession of its foreign sites, including the Merck & Co. subsidiary in the United States. Merck & Co., which operates as Merck Sharp and Dohme (MSD) outside the U.S. and Canada, is now an independent company. Merck KGaA operates mainly in Europe, Africa, Asia, Oceania and Latin America. Since Merck & Co. holds the rights to the Merck name in the U.S. and Canada, the company operated under the umbrella brand EMD Chemicals in North America, and since 2010 as EMD Millipore (after the acquisition of Millipore Corporation), formed from the initials of Emanuel Merck, Darmstadt. Founded in 1668 in Darmstadt, Merck KGaA of Darmstadt, Germany, is the world's oldest pharmaceutical and chemical company. The success of the export business to the United States led in 1887 to the establishment of an office in New York, which gave rise to their subsidiary [Merck & Co.](http://www.crunchbase.com/organization/merck-co-inc) four years later. Owing to World War I, Merck & Co. was expropriated in 1917. The two companies have been separate every since.  Merck KGaA Subsidiaries: - [Merck Consumer Healthcare](http://www.crunchbase.com/organization/merck-consumer-healthcare) - [Merck Performance Materials](http://www.crunchbase.com/organization/merck-performance-materials)

Merck

ArrowMark Partners is an SEC-registered investment adviser. It aims to provide consistent, asymmetric, non-correlated, risk-adjusted returns by utilizing fundamental research across the capital structure. They are committed to compounding wealth by providing one-of-a-kind, client-driven, and absolute return solutions.

ArrowMark Partners

A fundamental investment philosophy of ‘Building on principles’ guides us at Mirae Asset. Over the years, these principles have enabled us to become Asia’s premier financial group and created new trends in the Asian capital market.  Above all, we put our clients’ interests first, always adhering to high ethical standards. Because our success clearly comes from their success, we use fundamental investment principles to identify opportunities that generate value and lasting profits.  We are strong believers in teamwork and are determined to recruit the best and brightest people as we open new horizons in Asia and expand globally. Just as we strive to continually improve our own performance, Mirae Asset is committed to helping every community it joins.  On behalf of the entire Mirae Asset Financial Group, I would like to convey the sense of responsibility your trust in us merits and pledge to do all that we can to exceed your expectations.

Mirae Asset Venture Investment

The MRL Venture Fund is the Cambridge, MA – based independent venture capital investment group within Merck Research Laboratories, the R&D division of Merck & Co., Inc. MRL Ventures creates and/or invests in seed and early-stage therapeutics companies, based on translatable breakthrough science, with the potential to deliver highly differentiated new medicines to improve human health.

MRL Ventures Fund

Pappas Capital invests exclusively in the life science sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures – across the United States and Canada. They operate three lines of business: Pappas Ventures, their flagship venture arm; Specialized Fund Management, where we create and manage custom-tailored investment vehicles; and Translational Medicine, where we partner with research universities to accelerate the development of their scientific discoveries and inventions.

Pappas Capital

NS Investment (NSI) is an affiliated firm of Dong-A ST, a leading pharmaceutical company in the Republic of Korea. NSI was established in 2015 to independently manage venture capital funds and serve institutional investors in Korea. NSI is focused on meeting the financial objective of its fund investors. NSI seeks to link Korean investor capital with innovative companies beyond its domestic boarders and ultimately link entrepreneurs and science across continents.

NS Investment

Cowen Healthcare Investments invests fiduciary capital in healthcare companies across the biopharma, diagnostics and digital health sectors.

Cowen Healthcare Investments

Aktis Oncology

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor-targeting agents with ideal properties for alpha radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology's molecules will quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing the side effects of treatment. This approach would also enable clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes.

Aktis Oncology is a biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals for the treatment of a broad range of solid tumors. The company has developed proprietary platforms to generate tumor-targeting agents with optimal properties for alpha radiotherapy. Aktis' proprietary technology leverages the potent anticancer effects of alpha radiation to selectively target and penetrate deep into tumors while rapidly clearing from healthy tissues, maximizing tumor elimination and minimizing side effects.

AKTIS ONCOLOGY RAISES $84 MILLION TO ADVANCE NOVEL TARGETED ALPHA RADIOPHARMACEUTICALS

AKTIS ONCOLOGY ENTERS INTO STRATEGIC COLLABORATION WITH LILLY TO DISCOVER AND DEVELOP NOVEL ANTICANCER RADIOPHARMACEUTICALS

AKTIS ONCOLOGY EXPANDS SCIENTIFIC ADVISORY BOARD TO ADVANCE PIPELINE OF TARGETED ALPHA RADIOPHARMACEUTICALS

Merck backs radiopharmaceutical startup Aktis, joining other high-profile backers

AKTIS ONCOLOGY TO PARTICIPATE IN 2023 GUGGENHEIM HEALTHCARE TALKS: RADIOPHARMACEUTICALS DAY

Lilly Inks Potential $1.1B Radiopharma Deal with Aktis Oncology

Radioactive materials open up new pathways in patient treatment and medication

Radiopharmaceuticals

AKTIS ONCOLOGY TO PARTICIPATE IN THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE

Aktis Oncology is a biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals for the treatment of a broad range of solid tumors. The company has developed proprietary platforms to generate tumor-targeting agents with optimal properties for alpha radiotherapy. Aktis' proprietary technology leverages the potent anticancer effects of alpha radiation to selectively target and penetrate deep into tumors while rapidly clearing from healthy tissues, maximizing tumor elimination and minimizing side effects.
Aktis' lead program targets Nectin-4, a tumor-associated antigen found in urothelial and other cancers. The company's growing oncology pipeline comprises seven programs, including the Nectin-4 targeting clinical-stage program. Aktis' molecules are designed to enable clinicians to visualize and verify target engagement prior to administering the therapeutic radioisotopes.
In May 2024, Aktis entered a strategic collaboration with Eli Lilly and Company to discover and develop novel anticancer radiopharmaceuticals utilizing Aktis' proprietary miniprotein discovery platform. Under the agreement, Lilly obtained worldwide rights to develop radiopharmaceutical products discovered by Aktis on a defined set of targets selected by Lilly. Aktis received a USD 60 million upfront payment and an equity investment from Lilly, and is eligible for up to USD 1.1 billion in milestone payments and royalties on sales.

Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, developed the first radioactive diagnostic agent approved by the US Food and Drug Administration (FDA) for imaging tau neurofibrillary tangles on positron emission tomography (PET) scans. The F-18 flortaucipir tracer, marketed under the name Tauvid, helps clinicians estimate the density and distribution of tau tangles in the brains of adults with cognitive impairment being evaluated for Alzheimer's disease.
Tauvid works by binding to tau proteins that form neurofibrillary tangles, which are a hallmark of Alzheimer's disease along with amyloid plaques. Previously, doctors could only diagnose Alzheimer's neuropathologically by identifying both plaques and tangles in the brain after death. With Tauvid, physicians can now visualize and assess tau pathology in living patients through PET imaging.
The FDA's approval of Tauvid in May 2020 was supported by two clinical studies evaluating the agent's safety and effectiveness. These studies demonstrated that readers interpreting Tauvid PET scans had a high probability of accurately detecting tau pathology and an average-to-high probability of correctly identifying patients without tau pathology.

Avid Radiopharmaceuticals

Trevarx is a biomedical company focused on developing radiopharmaceutical technologies to combat breast, ovarian, and prostate cancer. The company specializes in small molecule radiopharmaceuticals, offering a unique theranostic solution. Trevarx's approach combines therapeutic and diagnostic capabilities, potentially enhancing cancer treatment efficacy. The company leverages its expertise in scientific research and multi-center trials to advance its radiopharmaceutical technologies. Trevarx's business model includes providing support for multi-center trials, regulatory assistance, and GMP (Good Manufacturing Practice) manufacturing. These services aim to accelerate the commercialization process of their radiopharmaceutical technologies. The company's team comprises experts with extensive experience in the field, positioning Trevarx to efficiently develop and bring its solutions to market.

Trevarx Biomedical

Alpha Source is a company that manufactures and supplies alpha radiation sources, primarily composite alpha sources containing Pu-239, Am-241, and Cm-244 radionuclides electroplated onto platinum or platinum-clad nickel foils. These sources are designed for alpha spectroscopy systems, providing alpha particles in the energy range of approximately 5100 to 5800 keV with line widths typically less than 20 keV FWHM. This wide energy range allows for valid energy calibration of most alpha-emitting nuclides. Alpha Source offers its composite alpha sources in three configurations: A-1, A-2, and PM. The sources are uncovered and have an active area of 5.0 mm. When purchased as NIST traceable standards, the sources can also be used to determine detector efficiencies for alpha particles, with total and individual activities provided on the Certificate of Calibration.
In addition to its core alpha source product line, Alpha Source also provides nationwide service for extending the life of ultrasound imaging equipment through preventative maintenance and quality replacement parts. The company offers high-quality replacement parts for biomedical equipment, along with value-added services to streamline supply chain operations.
Alpha Source has over 30 years of expertise in manufacturing and sourcing high-quality medical replacement battery packs, offering solutions that optimize battery life and costs for healthcare facilities.

Alpha Source

Ionetix is a cyclotron technology and isotope manufacturing company based in the US. It developed the world's first commercial compact superconducting cyclotron, the ION-12SC, which is used to produce N-13 Ammonia, a highly accurate Positron Emission Tomography (PET) imaging agent for detecting Coronary Artery Disease (CAD). The company's proprietary cyclotron technology platform enables access to scarce radioisotopes used for diagnostic and therapeutic radiopharmaceuticals.
Ionetix's cyclotrons can produce high-purity alpha-emitting radionuclides like Actinium-225 (Ac-225) and Astatine-211 (At-211), which are utilized in targeted alpha therapies for cancer treatment. In April 2023, the company successfully produced Astatine-211 at its new Alpha Isotope Manufacturing facility in Lansing, Michigan, using a 30 MeV cyclotron. This facility is dedicated exclusively to producing alpha-emitting radionuclides via cyclotrons. In June 2024, Ionetix announced the successful production of Actinium-225, marking a pivotal milestone as the first commercial cyclotron-produced Ac-225.
Ionetix's business model involves establishing a network of ION-12SC cyclotrons installed on or near the campuses of PET programs across the US. The company covers the costs related to installation and operation, making N-13 Ammonia available to providers through a pay-by-the-dose model, ensuring accessibility and affordability. Ionetix also provides N-13, F-18, and Ga-68 for diagnostic imaging. Its distribution supply chain includes contract drug manufacturing and "white glove" distribution logistics, enabling global access to these imaging agents and targeted radiotherapies.

Ionetix

Therapeia GmbH & Co. KG is a German specialist company focused on developing diagnostic and therapeutic radiopharmaceuticals to address unmet patient needs. Their lead product candidate, ACD-101, is a family of products for the diagnosis and treatment of malignant glioma (brain cancer). ACD-101 combines several anti-cancer effects within a single molecule, including cytostatic properties, an intrinsic radio-sensitizer effect that enhances the efficacy of external radiation therapy (the current standard treatment), and the ability to be radiolabeled with 131I for intracellular 131I-irradiation ("endo-radiotherapy"), similar to radioiodine therapy used for thyroid cancer.
ACD-101 is actively transported across the intact blood-brain barrier and accumulates in tumor tissue, where it is retained for up to a week. This intratumor accumulation occurs independently of histological tumor type in both low and high-grade gliomas (WHO grades II-IV), allowing for universal therapeutic use regardless of glioma histology. In a rat model, experimental human gliomas were curatively treated for the first time using 131I-ACD-101. This endo-radiotherapy can be combined with conventional external radiotherapy to maximize synergies of different anti-tumor modes of action.

Therapeia GmbH & Co. KG

Companies that use radioactive isotopes to develop medication for the treatment of diseases in patients.

Companies that use radioisotopes to develop solutions for the diagnosis of patients. Solutions are typically synthesized for internal use on patients and are employed in tandem with a diagnostic imaging device to identify disease or causes of diseases.

Companies that produce and supply radioisotopes to pharmaceutical companies creating radiopharmaceuticals.

Companies providing support services to radiopharmaceutical-related companies. These include testing services, research, and training.

Some drug developers use connected medical devices for monitoring treatment administration and drug development

Aktis Oncology

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless